Dr . Rubina Zulfqar
Faisalabad, Punjab Province, 38000, Pakistan
Location status: Recruiting
NCT Number: NCT07703332
Upper-limb overuse syndrome (ULOS) often arises from repetitive loading, altering cervical biomechanics and increased median-nerve mechano sensitivity. Elongation longitudinal decoaptation ostéo-articulaire (ELDOA) at C5-C6 improves segmental decompression and neural sliding, while Active isolated stretching (AIS) enhances soft tissue elasticity and neuro dynamic glide.
Currently no direct comparison exists between these two methods in literature. Study aims to compare ELDOA (C5-C6 specific) and AIS in patients with ULOS for checking effects on median nerve mobility and pain. This research will be conducted as a randomized clinical trial involving 84 participants (42 in each group). Adults aged 20-50 years with diagnosis of ULOS, symptom duration 3- months (12 weeks) will be included in the study. While Neurological or rheumatologic conditions, recent corticosteroid injections, recent cervical or major upper limb surgery, and ongoing neural mobilization-focused physical therapy are among the exclusions. After meeting the inclusion and exclusion criteria and obtaining written and verbal consent from the participants. Participants will be randomly assigned to either the AIS or ELDOA groups and will receive 3 sessions per week for 3 weeks with baseline hot pack. Group A will perform diaphragmatic breathing with ELDOA targeting C5-C6, whereas Group B will engage in AIS on muscles that cause median-nerve tension. Pain intensity, upper limb function and median nerve mobility are outcome measures that will be assessed using tools NPRS, QuickDASH and ULTT1. Data will be analyzed using the 2024 SPSS.
Interested in participating?
Request Info20 year–50 year
All sexes
Interventional
Not applicable
Faisalabad, Punjab Province, 38000, Pakistan
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Common baseline treatment (both Groups) Prior to their designated intervention, both groups will receive the following standardized baseline treatment:
Time frame: 3 weeks
Pain intensity will be measured by using numeric pain rating scale
Time frame: 3 weeks
Functional status/ Disability will be measured by using QuickDASH questionnaire, The lower the Quick DASH score, the better the upper limb function and fewer the activity limitations.
Time frame: 3 weeks
Nerve mobility will be measured by using Upper Limb Tension Test (ULTT1), Better responses in the ULTT1 suggest better median nerve mobility and lower neural tension.
Contact information is provided by the study sponsor or research team.
University of Faisalabad
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.